Duchenne Muscular Dystrophy : First child dosed in Clinical Trial of Investigational Gene therapy

A first patient suffering from Duchenne muscular dystrophy received a first dose of the investigational gene therapy GNT0004 in an international phase I/II/III multicener trial for which Genethon is the sponsor.

More information on the gene therapy clinical trial lead by Genethon.